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Abstract
Human h-hexosaminidase A (Hex A) (ah) is composed of two subunits whose primary structures aref 60% identical. Deficiency of
either subunit results in severe neurological disease due to the storage of GM2 ganglioside; Tay–Sachs disease, a deficiency, and Sandhoff
disease, h deficiency. Whereas both subunits contain active sites only the a-site can efficiently bind negatively charged 6-sulfated
hexosamine substrates and GM2 ganglioside. We have recently identified the aArg424 as playing a critical role in the binding of 6-sulfate-
containing substrates, and hAsp452 as actively inhibiting their binding. To determine if these same residues affect the binding of the sialic acid
moiety of GM2 ganglioside, an aArg424Gln form of Hex A was expressed and its kinetics analyzed using the GM2 activator protein:[3H]-
GM2 ganglioside complex as a substrate. The mutant showed af 3-fold increase in its Km for the complex. Next a form of Hex B (hh)
containing a double mutation, hAspLeu453AsnArg (duplicating the a-aligning sequences), was expressed. As compared to the wild type
(WT), the mutant exhibited a >30-fold increase in its ability to hydrolyze a 6-sulfated substrate and was now able to hydrolyze GM2
ganglioside when the GM2 activator protein was replaced by sodium taurocholate. Thus, this a-site is critical for binding both types of
negatively charge substrates.
D 2002 Elsevier Science B.V. All rights reserved.
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The h-hexosaminidases (Hex) are lysosomal hydrolases
that catalyze the cleavage of terminal h-N-acetylglucos-
amine or h-N-acetylgalactosamine from a broad range of
glycoconjugated substrates. In normal human tissues, two
major Hex isozymes predominate, Hex A (ah) and Hex B
(hh). Hex A is a heterodimer composed of an a and a h
subunit. The a subunit is encoded by the HEXA gene
mapped to chromosome 15q23–q24 [1]. The h subunit is
encoded by the HEXB gene which maps to chromosome
5q13 [2]. In addition to these, a very small amount of an
unstable acidic isozyme, Hex S (aa), can be found in cells
from patients deficient in the h protein (Sandhoff patients,
see below) (reviewed in Ref. [3]).
The primary structure of the a and h subunits are
approximately 60% identical and therefore must share very
similar three dimensional structures with conserved func-
tional domains. Whereas no previous data have identified an
active monomeric subunit the existence of the three Hex
isozymes, containing all possible dimeric combinations of
the two subunits, necessitates each subunit to contain all the
residues necessary to form an active site (reviewed in Refs.
[4,5]). It is likely that the dimer interface occurs at or near
enough to the active sites that some residues in the opposing
subunit either complete or stabilize the active site of the
other. Whereas all three isozymes can cleave terminal non-
reducing h1–4 linked glycosidic bonds of either amino
sugar (GlcNAc or GalNAc), contained on substrates such as
Asn-linked oligosaccharides on proteins or on neutral gly-
colipids, only a subunit-containing isozymes (Hex A or Hex
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S) can cleave h1–4 linked GlcNAc-6-sulfate residues from
keratan sulfate, and only heterodimeric Hex A can cleave
the h1–4 linked GalNAc from the sialic acid-containing
GM2 ganglioside. Artificial substrates have been developed
that mimic these natural groupings. 4-Methylumbelliferyl-2-
acetamido-2-deoxy-h-D-glucopyranoside (MUG) is cleaved
by all three isozymes and therefore is used to measure
‘‘total’’ Hex activity. 4-Methylumbelliferyl-2-acetamido-2-
deoxy-h-D-glucopyranoside-6-sulfate (MUGS) is cleaved
primarily by the a-subunit containing isozymes (Hex A
and S). However, the h active site can slowly hydrolyze this
substrate with MUG/MUGS ratios of 150–300: 1 for Hex
B, 3–4: 1 for Hex A, and 1–1.5: 1 for Hex S [6]. The only
substrate completely unique to one of the Hex isozymes,
Hex A, is GM2 ganglioside. The hydrolysis of GM2
ganglioside to free N-acetylgalactosamine and GM3 gan-
glioside also requires the assistance of a small thermostable
protein known as the GM2 activator protein (Activator).
This protein binds GM2 ganglioside, and presents it to the
Hex A isozyme for hydrolysis. In vivo, therefore, it is the
Activator:GM2 complex that is the true Hex A-specific
substrate. Although the Activator interacts primarily with
the a subunit and thus can bind both Hex A and Hex S,
elements of the h subunit are needed to allow the h-GalNAc
residue of GM2 to be properly orientated in the a active
site for hydrolysis [8], i.e. Hex S may be able to bind the
complex, but it cannot hydrolyze GM2 [9]. Thus, genetic
defects in any one of three gene products (a subunit, h
subunit, and Activator) can result in impaired hydrolysis and
intra-lysosomal accumulation of GM2. This accumulation is
seen most dramatically in neuronal tissues where synthesis
of this important brain lipid is greatest. Collectively these
diseases are known as the GM2 gangliosidoses, which
consist of Tay–Sachs disease (HEXA mutations), Sandhoff
disease (HEXB mutations), and the AB-variant form of the
disease (GM2A mutations) [3,4].
Human Hex A and B are members of the family 20
glycosidases. This group of proteins from many different
organisms are believed to be evolutionarily and, thus,
structurally related. Based on the crystal structure for one
member of this family of proteins, a bacterial chitobiase, a
model for human Hex was developed [11]. However, the
bacterial enzyme shares sequence identity with the human
enzyme only in its active site region and then only at a level
of 26%. Additionally, it exists as a monomer. Previous work
from our lab [12–14] and others [15,16] has demonstrated
experimentally that this model of the active site is at least
partially accurate. Recently using this model, we [12] and
Kaplan et al. [17] identified aArg424 as the residue most
likely to be involved in the direct binding of the 6-sulfate
group of the artificial substrate MUGS by Hex A and S. In
our previous report Hex S was purified from CHO cells
transfected with an a subunit cDNA which carried various
site specific mutations, one of which was aArg424Gln. This
mutation raised the Km of Hex S for MUGS ninefold.
Tranfection of CHO cells with a human [18–20] acDNA
produces only Hex S, because few, if any, inter-species
dimers form [6,13]. In this report we produce Hex A
containing the mutant [or wild-type (WT)] a-subunit by
permanently transfecting a transformed glial cell line from
a Tay–Sachs patient with the appropriate acDNA [15]. After
ion-exchange separation of the isozymes, the mutant and WT
Hex A could be tested using [3H]-GM2 and purified human
Activator. In our previous report we also attempted to
analyze Hex B containing hAspLeu453AsnArg substitutions
(hAspLeu453 aligns with aAsnArg424). Although mutant
Hex B levels were low, possibly due to its partial recognition
by the endoplasmic reticulum’s quality control system [8],
we were able to document a large increase in its hydrolytic
efficiency towards MUGS. In this report we express this
mutation along with additional sequences encoding a C-
terminal His6-tag for easy purification [13,14] and re-analyze
its MUG/MUGS hydrolysis ratio. More importantly, we
assess its ability to hydrolyze GM2 in an assay where the
function of the Hex A-specific Activator is replaced by a
nonspecific detergent (reviewed in Ref. [10]).
1. Materials and methods
1.1. DNA construction and mutagenesis
As previously described [12], site-directed mutagenesis
was used to create the Arg424Gln a-subunit mutation carried
in the pREP4 expression vector. The hAspLeu453AsnArg
double mutation was created as described previously [12]. A
section of the hcDNA containing the mutations was excised
using BstX1 and then subcloned into a similarly digested C-
terminal His6-tag encoding h-construct in the pcDNA3.1
vector [13] using standard techniques.
1.2. Hex A and Hex B from human placenta
Human Hex A and B were purified from human placenta
as previously reported [21].
1.3. Cell culture and DNA transfections
Transformed Tay–Sachs neural glial cells (TSD-NG,
from Fernandes et al. [15]) were grown in a-minimum
essential medium (a-MEM) with 15% fetal calf serum
(FCS) and antibiotics at 37j in 5% CO2. Transfections were
performed according to the Superfect reference manual from
Qiagen. The neural glial cells were seeded overnight in 100-
mm tissue culture dishes and grown until they were about
80% confluent (overnight). For each dish of cells being
transfected, 10 Ag of DNA was mixed with 60 Al of
Superfect in 300 Al of serum-free a-MEM. The mixture
was allowed to incubate for 10 min at room temperature to
form the DNA–Superfect complexes. Three milliliters of a-
MEM containing serum was added prior to being added
dropwise to the culture dishes. The dishes were incubated at
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37j for 3 h, after which the cells were washed and then fed
with a-MEM containing 15% FCS for 48 h. Following this,
the cells were fed a-MEM plus 15% FCS and 1 Al/ml of
hygromycin B (Calbiochem) every 2 days. After drug
selection for 1 month, the mixed colonies were trypsinized
and the cells were passaged into larger dishes for further
growth and analyses. Hygromycin B was present in the
growth media of all stable transfectants. The mutant Hex B
construct in pcDNA 3.1 was transfected into CHO cells
essentially as described as above except that the media used
for growth contained 10% FCS and with drug selection
being performed with 400 Ag/ml neomycin.
1.4. Separation of Hex A by diethylaminoethyl (DEAE) ion-
exchange chromatography
Cell pellets collected from the stably transfected neural
glial cells containing either the WT or aArg424Gln Hex A
mutant (Q mutant) construct cells were kept at  20 jC
until use. Cells were lysed by multiple freeze–thaw cycles
in 10 mM phosphate buffer pH 6. Following centrifugation,
the lysate (10-mg total protein for WT, 20-mg total protein
for Q mutant) was applied directly onto a 2-ml column of
DEAE Sepharose CL-6B (Pharmacia) pre-equilibrated with
10 mM phosphate buffer pH 6. The column was washed
with this phosphate buffer and then fractions eluted using a
NaCl gradient (from 0 to 300 mM NaCl) in 10 mM
phosphate buffer pH 6 [6]. Fractions were assayed for
MUG and MUGS specific activity as described below.
Appropriate fractions were pooled and concentrated using
BSA-pretreated Centricon YM-10 spin concentrator.
1.5. Separation of the mutant Hex B by metal affinity
chromatography
Large plates (Falcon P150) of transfected CHO cells were
initially subcultured using a-MEM containing 10% FCS.
When the cells were 80% confluent, the cells were washed
well with PBS and then the media was changed to serum-free
media (CHO SFMII, Gibco). After 4 days, the media was
collected and replaced. This procedure was repeated twice
more. The media was pooled, centrifuged at 3000 rpm, and
the pellet discarded. The cleared media (200 ml) was con-
centrated to 50 ml using a centrifugal concentrator device
(Millipore Ultracell 80, 10 kDa cut-off). The concentrated
media was then dialyzed against buffer (20 mM imidazole,
500 mM NaCl, 50 mM NaH2PO4, 1% Tween 20, and 10%
glycerol, pH 8.0). This dialyzed media was then transferred
into a tube containing 400 Al of washed QIAGEN Ni–NTA
resin and rotated at 4 jC overnight. The resin was packed
into a column and then washed with 20 ml of the same buffer.
The column was washed further with 20 ml of same buffer
containing 100 mM imidazole. The mutant Hex B was eluted
with 3 ml of this buffer containing 250 mM imidazole,
collecting 0.5-ml fractions. MUG and MUGS specific activ-
ity was determined. Fractions containing the highest activity
were combined and then concentrated using a BSA-pre-
treated Centricon YM-10 spin concentrator.
1.6. Hex activity assay
Hex activity was measured using MUG and MUGS
substrates as previously reported [22] using 1.6 mM MUG
or MUGS substrate incubated at pH 4.2 in citrate-phosphate
buffer at 37 jC for 15 min or 1 h, respectively. Fluorescence
measurements were performed on an LS-50B Perkin Elmer
Fluorescence Spectrometer with sipper attachment.
1.7. Preparation of GM2 ganglioside-containing liposomes
The hydrolysis of glycolipids in general has been shown
to be enhanced by their presence in liposomes containing
other anionic lipids [23]. Thus, liposomes containing
tritiated GM2 ganglioside and other lipid components were
prepared essentially as previously described [7]. Briefly,
[3H]-GM2 ganglioside (4680 cpm/nmol, 10 mol%), cho-
lesterol (20 mol%), phosphatidyl inositol (20 mol%), and
phosphatidyl choline (50 mol%) were dried down under
high vacuum so that upon rehydration a final lipid con-
centration of either 2 or 4 mM could be achieved. The
lipid mixture thus obtained was rehydrated in 2 mM Tris/
HCl buffer pH 7.4 and then freeze–thawed 10 times to
ensure solute equilibration between bulk and trapped
solutions. Unilamellar vesicles were prepared by succes-
sive passage of the rehydrated lipid suspension through
polycarbonate filters of various pore size (Avestin, 400,
200, and 100 nm) mounted in a mini-extruder (Liposo-
Fast, Avestin), with 19 passes as recommended by the
manufacturer’s literature.
1.8. GM2 ganglioside hydrolysis kinetics
The standard incubation mixture for the hydrolysis reac-
tions using GM2 ganglioside-containing liposomes con-
tained the following components with a final volume of
100 Al; citrate-phosphate buffer (pH 4.1, 20 mM), bovine
serum albumin (50 Ag/ml), GM2 activator protein (isolated
and refolded from E. coli as previously described [7,24], 2
Ag), Hex A constructs (various amounts), and GM2-contain-
ing liposomes (as prepared above, 50 Al, 0–120 AM of 3H-
GM2). After an 18-h incubation, the reaction was stopped by
the addition of 1 ml of chloroform and 1 ml of 12 mM citrate-
phosphate buffer containing 13.6 mM GlcNAc. The hydro-
lyzed product from GM2, [3H]-GalNAc, was separated from
the unreacted substrate by passage through a positively
charged ion-exchange 0.6 ml mini-column of AG3X4 (ace-
tate form) resin (BioRad). The unbound fraction containing
[3H]-GalNAc was determined by liquid scintillation count-
ing. Less than 10% of the total input substrate counts was
hydrolyzed and released during the reaction.
Experiments to establish the kinetics of the WT Hex A
and mutant construct with respect to amount GM2 ganglio-
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side added were performed by varying the amount of the
substrate liposomes containing GM2 ganglioside added to
the reaction mixture. Kinetics with respect to amount of
GM2 added were performed essentially as described above
except that liposomes were prepared at a higher concen-
tration (4 mM) prior to addition into the final assay volume.
Kinetic constants were calculated using a computerized
nonlinear least squares curve-fitting program for the Mac-
intosh, KaleidaGraph 3.0. This method provided the best
estimation of the kinetic parameters [25]. Standard errors
were calculated from the best-fit curve generated by the
computer program.
1.9. GM2 hydrolysis by Hex B mutants
This assay does not utilize liposomes or the Activator;
their functions being replaced by sodium taurocholate
[18,20,26]. The incubation mixture for these assays con-
tained the following components in a final volume of 100
Al; citrate-phosphate buffer (pH 4.1, 20 mM), bovine serum
albumin (50 Ag/ml), Hex enzyme (Hex B WT or the double
mutant hAsp452Asn; hLeu453Arg Hex B), sodium taurocho-
late (final concentration 10 mM), and [3H]-GM2 ganglio-
side (6 nmol, 17,000 cpm/nmol). After a 4-h incubation at
37 jC, the samples were processed as above and the
unbound fraction containing [3H]-GalNAc was counted
using liquid scintillation counting.
2. Results
To examine whether the amino acid residue involved in
sulfate binding of the MUGS substrate might also be
involved in binding the sialic acid residue of GM2 ganglio-
side, constructs encoding the conservative substitution
aArg424Gln (Q Hex) and WT a were permanently trans-
fected into a transformed Tay–Sachs neural glial cell line.
Hex A, WT, and Q Hex A were analyzed after removal of
small amounts of residual Hex B and S by ion-exchange
chromatography (data not shown). Kinetic examination of
the partially purified Hex A forms was then performed using
50 Al of liposomes containing various amount of GM2
ganglioside (0–120 AM). This enhanced assay system was
critical in that it allowed us to assay very small amounts of
the partially purified Hex A forms. As well, using this
system produced a typical Michaelis–Menten saturation
curve, where we have previously assayed constant amounts
of Hex A and Activator with various amounts of GM2
alone, i.e. in a micellar assay, up to 200 AM, without
observing any indication of substrate saturation, making
Km and Vmax calculations impossible (unpublished data).
When each form of Hex was assayed using the liposome
based assay conditions, differences between WT Hex A and
the Q Hex A were observed (Fig. 1). Pure placental Hex A
and WT Hex A were found to have Km values for the
Activator:GM2 complex which were not significantly differ-
ent (Table 1). Their Vmax values were slightly different, but
this likely reflected an estimated 1% contamination by Hex
B in the WT and presumably mutant Hex A preparations (as
calculated from the slightly higher MUG/MUGS ratio of the
WT Hex A as compared to the pure placental Hex A (Table
1)). However, due to the fact that Hex B is inactive towards
the GM2/Activator complex this would have no effect on
the resulting Km’s. Significantly, the Km of Q Hex A for the
complex was increased by approximatelyf 3-fold while its
Fig. 1. Kinetic examination of pure placental WT Hex A (closed triangles),
WT Hex A derived from transfected glial cells (closed squares), and Q Hex
A (aArg424Gln) also derived from transfected glial cells (closed diamonds),
using varying amounts of [3H]-GM2 ganglioside contained in 50 Al of
liposomes and saturating amounts of Activator protein as a substrate.
Experimental data points are shown with the computer generated best-fit
curve overlaid. Velocity values are given in nmol [3H]-GM2 ganglioside
hydrolyzed/h/Ag Hex A (estimated from its known SA towards MUG).
Table 1
Characterization of the artificial substrate specificity and Km and Vmax for
the Activator:GM2 complex of each isozyme
Forms of Hex MUG/
MUGSa
Km
(AM GM2)
Vmax [pmol GM2
h 1 U 1 (MUG)]b
Pure Hex Ac 3.5 46F 15c 0.008F 0.001
WT Hex Ad 5.4 39F 11 0.004F 0.001
NQ Hex Ae 59 120F 15 0.051F 0.004
Pure Hex Bc 190 NDf ND
WT Hex Bg 150 ND ND
NR Hex Bh 4.5 ND ND
a The ratio of units of MUG to MUGS hydrolyzed by the indicated
forms of Hex at pH 4.2 with substrate concentration of 1.6 mM.
b Vmax was normalized using the total units (nmol/h) of MUG activity
added to the assay.
c Hex A and Hex B purified from human placenta [21].
d Hex A was isolated from transformed Tay–Sachs neural glial cells
permanently transfected with the wild-type encoding acDNA.
e Hex A was isolated from transformed Tay–Sachs neural glial cells
permanently transfected with an Arg424Gln encoding acDNA.
f Not determined.
g Hex B was isolated through a His6-tag from the media of CHO cells
transfected with the wild-type encoding hcDNA.
h Hex B was isolated through a His6-tag from the media of CHO cells
transfected with an hAsp452Asn; hLeu453Arg encoding hcDNA.
R. Sharma et al. / Biochimica et Biophysica Acta 1637 (2003) 113–118116
Vmax was increased by f 10-fold. In addition, the MUG/
MUGS hydrolysis ratio for Q Hex A, as compared to pure
Hex A or WT Hex A, was increased approximatelyf 10
fold.
We have previously identified residues in both subunits
that control the efficiency of MUGS binding. The aArg424
(aligns with hLeu453) enhances, whereas hAsp452 (aligns
with aAsn423) actively inhibits binding of MUGS [12].
Thus, substitutions for these residues were made in the
hcDNA to make it more a-like, i.e. hAspLeu453AsnArg
(NR Hex B). The constructs encoding WT Hex B and NR
Hex B also encoded a C-terminal His6-tag which allowed
purification of each isozyme from the media of the trans-
fected cells using metal-affinity chromatography. The
MUG/MUGS hydrolysis ratio for NR Hex B was decreased
>30-fold (Table 1), but was still three- to fourfold higher
than WT Hex S [12]. When the abilities of WT Hex A and
Hex B to hydrolyze [3H]-GM2 in the presence of detergent
[18,20,26], were compared to that of NR Hex B, af 4-fold
increase over WT Hex A levels was observed, whereas WT
Hex B had no detectable activity (Table 2). Taken together
these data indicate that the same residues affect both the
binding of 6-sulfate-containing hexosamines and the sialic
acid moiety of GM2.
3. Discussion
Of the three Hex isozymes only heterodimeric Hex A
(ah) appears to be essential for life, as it can hydrolyze all
known Hex substrates. Although Hex B (hh) and Hex S
(aa) are functional toward many of the same substrates,
only Hex A can utilize the Activator:GM2 complex as a
substrate. There are at least two reasons for this; first,
Activator-docking requires interaction with portions of both
the a and h subunit and second, only the a-active site can
efficiently bind GM2. Thus, both Hex A and S can hydro-
lyze GM2 when the Activator’s function is replaced by a
detergent. However, even in the presence of detergent, Hex
B cannot efficiently hydrolyze GM2. That this a-specificity
is caused by the presence of the negatively charged sialic
acid residue of GM2 has been extrapolated from the
observation that Hex B can hydrolyze the asialo-derivative
of GM2, GA2, in the presence of detergent better than Hex
A. Similarly the presence of a negative charge from a 6-
sulfate group on h-linked GlcNAc substrates also appeared
to convey a-specificity to the substrate (reviewed in Refs.
[3,10]). Two questions remained to be answered concerning
the mechanism by which the a-subunit obtains its unique
substrate-specificity: What are the differences in the a-
sequence as compared to h that allow it to bind these
negatively charged substrates? Are these two apparently
different negatively charged groups bound by the same site?
The first question was partially answered by us [12] and by
Kaplan et. al. [17], who identified the aligned sequence
aAsnArg424 and hAspLeu453 as promoting and inhibiting
the binding of the 6-sulfate group, respectively. However,
neither in these previous reports nor in the present study
(Table 1) has it been possible to completely convert the
specificity of Hex B for MUGS into that of Hex S by
substituting these two a-residues for their h-companions.
These data indicate that there is some as yet unidentified a-
residue(s) not conserved in the h-subunit, also involved in
MUGS-binding, that likely hydrogen bonds with aArg424.
The data presented in this report do clarify the second
question. Despite their apparent lack of structural similarity,
the sialic acid moiety of GM2 and the 6-sulfate group of
MUGS are bound by the same site in the a subunit; the
major residue involved in this binding being aArg424.
Conservative substitution of this residue with a neutral
Gln increases the Km’s of both MUGS binding to Hex S
(f 10-fold) [12] and Activator:GM2 complex binding to
Hex A (f 3-fold). Interestingly, whereas the Vmax of Q Hex
S for MUGS was slightly reduced, the Vmax of Q Hex A for
the complex was increasedf 10-fold (Table 1). The differ-
ence in the two results likely reflects the role of the
Activator, which participates in the binding of the complex
to Hex A. When Hex A and GM2 concentrations are held in
excess and the concentration of the Activator varied, the Km
of the reaction is 0.17 AM of Activator [27]. Thus, release
of the product, GM3, must be slow and perhaps rate-
limiting. The decreased affinity of Q Hex A for sialic acid
would affect its affinity for both GM2 and GM3, which
may facilitate the disassociation of the Activator:GM3
complex and increase the rate of GM2 turn over. This
hypothesis could also explain why the rate of GM2 hydrol-
ysis is 10-fold higher using taurocholate instead of the
Activator.
To confirm the role of aAsnArg424 in sialic acid binding,
we tested the ability of hAspLeu453AsnArg substituted Hex
B to hydrolyze GM2 in the presence of detergent. A
significant increase in hydrolysis from 0.00 to 0.10 pmol
GM2 h 1 U 1 (MUG) was noted (Table 2). Surprisingly,
this rate was about fivefold that of purified placental Hex A.
Some of this increase can be explained by the presence of
two functional active sites for GM2 in the mutant Hex B, as
compared to only one, the a-site, in Hex A.
Table 2
Pure Hex A and WT and NR forms of Hex B assayed using GM2 and a
nonspecific detergent, i.e. a taurocholate:[3H]-GM2 complex, as the
substrate
Form of Hex MUG units
added (nmol/h)
SA [pmol GM2
h 1 U 1 (MUG)]a
WT Hex Bb 48 0.000
NR Hex Bb 48 0.098
Pure Hex Ac 96 0.021
a Units (nmol/h) of MUG activity were used to calculate the specific
activity.
b Hex B was isolated from CHO cells transfected with either wild-type
or hAsp452Asn; hLeu453Arg encoding hcDNAs.
c Hex A purified from human placenta [17].
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